Liproca Depot Shows Promise for Treatment of Early-Stage Prostate Cancer

Liproca Depot Shows Promise for Treatment of Early-Stage Prostate Cancer
A new injectable flutamide formulation called Liproca Depot is safe, well-tolerated and shows sustained efficacy in untreated men with localized prostate cancer, according to early results of a Phase 2b clinical trial. The LPC-004 Phase 2b trial (NCT03348527) is ongoing at specialist urology clinics in Canada, Lithuania, and Finland. It aims to identify the optimal dose of Liproca Depot to be used in further testing, and to demonstrate the therapy's ability to prevent the progression of early-stage prostate cancer over a period of six months. Patient enrollment is ongoing. Find more information on locations and contacts here. Lidds' Liproca Depot combines NanoZolid — a technology to deliver cancer therapies — with 2-HOF (2-hydroxyflutamide). 2-HOF is a byproduct of flutamide, which is given as oral capsules in prostate cancer treatment under the brand name Eulexin. The experimental therapy is injected into the tumor region, after which NanoZolid forms a solid depot that will release the therapeutically active compound over a period of up to six months. This depot is absorbed harmlessly by the body as the active compound is released. “Administering Liproca Depot is similar to performing a prostate biopsy,” Laurence Klotz, MD, professor at the
Subscribe or to access all post and page content.